Informaは企業と専門家を数百の方法でサポートしています。

私たちの国際的なライブイベント、世界をリードする研究出版物、革新的なデジタルサービスのポートフォリオは、専門家が成功するために必要な知識と人脈を提供しています。

TIDES Asia: Oligonucleotide & Peptide Therapeutics
24-26 Feb, 2027
Grand Nikko Tokyo DaibaTokyo

David Lin, PhD
TS Pharma Experts LLC における President and Principal Consultant
スピーカー

プロフィール

Dr. David Lin is the principal consultant at TS Pharma Experts LLC, a regulatory consulting firm. He has over 29 years of pharmaceutical regulatory experience in the technical, quality and regulatory requirements for chemical (synthetic molecule), botanical and biopharmaceutical (biotechnological and biological) product development. He currently provides regulatory and technical assistance to biotech and pharmaceutical companies that is planning to conduct clinical studies and to obtain approval for the marketing of prescription products (drugs and biologics) in the United States. Dr. Lin received his Ph.D. in organic chemistry in the area of protein chemistry in 1989 and a M.B.A. in 2002. His regulatory product development expertise was developed at Biologics Consulting Group as a senior consultant and at FDA while working as a CMC reviewer, CMC Team Leader, acting Deputy Division Director, and acting Division Director in the Office of New Drug Chemistry in the Center for Drug Evaluation and Research (CDER). He has review experience in numerous therapeutic areas. In addition to his review and management duties, Dr. Lin was involved in the development of FDA guidances and good review practices. He is a member of numerous professional organizations including AAPS, DIA and RAPS.

アジェンダセッション

  • Regulatory CMC Challenges and Strategies for Oligonucleotide and Peptide Programs under Accelerated Review

    9:50am